Please enable JavaScript to continue using this application.

Compare $IVVD vs $TRDA | Chartloom

Compare

$IVVD vs $TRDA

Invivyd Inc · Entrada Therapeutics Inc

IVVD

Invivyd Inc

TRDA

Entrada Therapeutics Inc

Compare $IVVD vs $TRDA

Comparing Invivyd Inc and Entrada Therapeutics Inc

IVVDInvivyd Inc

TRDAEntrada Therapeutics Inc

IVVDInvivyd Inc

Market cap

$212M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.13x

Rev growth (TTM)

26.3%

YTD performance

-71.2%

52W performance

-56.0%

FCF yield

-51.6%

TRDAEntrada Therapeutics Inc

Market cap

$220M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.15x

Rev growth (TTM)

-94.1%

YTD performance

-43.6%

52W performance

-8.0%

FCF yield

-61.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IVVD

TRDA

Detailed metrics comparison

IVVD

Invivyd Inc

TRDA

Entrada Therapeutics Inc

Market Cap

IVVD$212M

TRDA$220M

Enterprise Value

IVVD$52M

TRDA$121M

Price

IVVD$0.72

TRDA$5.67

P/E Ratio

IVVDN/A

TRDAN/A

P/S Ratio

IVVD3.64x

TRDA46.97x

EV/Sales

IVVD0.90x

TRDA25.79x

EV/EBITDA

IVVD0.00x

TRDA15.47x

P/B Ratio

IVVD1.34x

TRDA0.90x

P/FCF Ratio

IVVDN/A

TRDAN/A

EV/FCF

IVVD-0.48x

TRDA-0.89x

PEG Ratio

IVVDN/A

TRDAN/A

Forward P/E (NTM)

IVVDN/A

TRDAN/A

Forward P/S (NTM)

IVVD3.13x

TRDA5.15x

Revenue (TTM)

IVVD$58M

TRDA$5M

Revenue Growth (YoY)

IVVD26.3%

TRDA-94.1%

Forward Rev Growth

IVVD44.8%

TRDA124.9%

Gross Margin (TTM)

IVVD92.2%

TRDA0.0%

Operating Margin (TTM)

IVVD0.0%

TRDA0.0%

EBITDA Margin (TTM)

IVVD-191.7%

TRDA-3686.8%

Net Margin (TTM)

IVVD-183.9%

TRDA-3537.7%

FCF Margin (TTM)

IVVD-187.9%

TRDA-2883.2%

Net Income (TTM)

IVVD$-107M

TRDA$-166M

FCF (TTM)

IVVD$-110M

TRDA$-135M

EPS (TTM)

IVVD-$0.33

TRDA-$3.93

ROE (TTM)

IVVD-5973.0%

TRDA-5761.0%

ROA (TTM)

IVVD-4897.0%

TRDA-4654.0%

ROIC (TTM)

IVVD-5973.0%

TRDA-5761.0%

Cash

IVVD$160M

TRDA$99M

Debt

IVVD$0

TRDA$0

Net Cash/Debt

IVVD$160M

TRDA$99M

Current Ratio (TTM)

IVVD5.87x

TRDA10.89x

Quick Ratio (TTM)

IVVD5.60x

TRDA10.47x

Debt/Equity (TTM)

IVVD0.00x

TRDA0.00x

Debt/Assets (TTM)

IVVD0.0%

TRDA0.0%

Interest Coverage (TTM)

IVVDN/A

TRDAN/A

Net Debt/EBITDA (TTM)

IVVD0.00x

TRDA0.00x

Beta

IVVD1.32

TRDA-0.22

52W Performance

IVVD-56.0%

TRDA-8.0%

YTD Performance

IVVD-71.2%

TRDA-43.6%

% from 52W High

IVVD-76.5%

TRDA-65.5%

% from 52W Low

IVVD36.7%

TRDA10.1%

Asset Turnover (TTM)

IVVD0.27x

TRDA0.01x

FCF Yield (TTM)

IVVD-51.6%

TRDA-61.4%

Earnings Yield (TTM)

IVVD-50.5%

TRDA-75.3%

Dividend Yield (TTM)

IVVDN/A

TRDAN/A

Rule of 40

IVVD-161.6

TRDA-2,977.3

EV/GP/RG

IVVD0.06

TRDAN/A

Ticker research

View IVVD research View TRDA research

Metric	IVVD Invivyd Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$212M	$220M
Enterprise Value	$52M	$121M
Price	$0.72	$5.67
P/E Ratio	N/A	N/A
P/S Ratio	3.64x	46.97x
EV/Sales	0.90x	25.79x
EV/EBITDA	0.00x	15.47x
P/B Ratio	1.34x	0.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.48x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.13x	5.15x
Revenue & Growth
Revenue (TTM)	$58M	$5M
Revenue Growth (YoY)	26.3%	-94.1%
Forward Rev Growth	44.8%	124.9%
Profitability
Gross Margin (TTM)	92.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-191.7%	-3686.8%
Net Margin (TTM)	-183.9%	-3537.7%
FCF Margin (TTM)	-187.9%	-2883.2%
Net Income (TTM)	$-107M	$-166M
FCF (TTM)	$-110M	$-135M
EPS (TTM)	-$0.33	-$3.93
ROE (TTM)	-5973.0%	-5761.0%
ROA (TTM)	-4897.0%	-4654.0%
ROIC (TTM)	-5973.0%	-5761.0%
Financial Health
Cash	$160M	$99M
Debt	$0	$0
Net Cash/Debt	$160M	$99M
Current Ratio (TTM)	5.87x	10.89x
Quick Ratio (TTM)	5.60x	10.47x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.32	-0.22
52W Performance	-56.0%	-8.0%
YTD Performance	-71.2%	-43.6%
% from 52W High	-76.5%	-65.5%
% from 52W Low	36.7%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.27x	0.01x
FCF Yield (TTM)	-51.6%	-61.4%
Earnings Yield (TTM)	-50.5%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-161.6	-2,977.3
EV/GP/RG	0.06	N/A
Ticker research	View IVVD research	View TRDA research

Valuation

P/S Ratio

IVVD

3.64x

TRDA

46.97x

EV/FCF

TRDA

-0.89x

IVVD

-0.48x

Growth & revenue

Revenue Growth TTM

IVVD

26.3%

TRDA

-94.1%

Forward Revenue Growth

TRDA

124.9%

IVVD

44.8%

Profitability & performance

Gross Margin

IVVD

92.2%

TRDA

0.0%

ROE

TRDA

-5761.0%

IVVD

-5973.0%

FCF Yield %

IVVD

-51.6%

TRDA

-61.4%

52-Week Performance

TRDA

-8.0%

IVVD

-56.0%

Detailed metrics comparison

IVVD

Invivyd Inc

TRDA

Entrada Therapeutics Inc

Market Cap

IVVD$212M

TRDA$220M

Enterprise Value

IVVD$52M

TRDA$121M

Price

IVVD$0.72

TRDA$5.67

P/E Ratio

IVVDN/A

TRDAN/A

P/S Ratio

IVVD3.64x

TRDA46.97x

EV/Sales

IVVD0.90x

TRDA25.79x

EV/EBITDA

IVVD0.00x

TRDA15.47x

P/B Ratio

IVVD1.34x

TRDA0.90x

P/FCF Ratio

IVVDN/A

TRDAN/A

EV/FCF

IVVD-0.48x

TRDA-0.89x

PEG Ratio

IVVDN/A

TRDAN/A

Forward P/E (NTM)

IVVDN/A

TRDAN/A

Forward P/S (NTM)

IVVD3.13x

TRDA5.15x

Revenue (TTM)

IVVD$58M

TRDA$5M

Revenue Growth (YoY)

IVVD26.3%

TRDA-94.1%

Forward Rev Growth

IVVD44.8%

TRDA124.9%

Gross Margin (TTM)

IVVD92.2%

TRDA0.0%

Operating Margin (TTM)

IVVD0.0%

TRDA0.0%

EBITDA Margin (TTM)

IVVD-191.7%

TRDA-3686.8%

Net Margin (TTM)

IVVD-183.9%

TRDA-3537.7%

FCF Margin (TTM)

IVVD-187.9%

TRDA-2883.2%

Net Income (TTM)

IVVD$-107M

TRDA$-166M

FCF (TTM)

IVVD$-110M

TRDA$-135M

EPS (TTM)

IVVD-$0.33

TRDA-$3.93

ROE (TTM)

IVVD-5973.0%

TRDA-5761.0%

ROA (TTM)

IVVD-4897.0%

TRDA-4654.0%

ROIC (TTM)

IVVD-5973.0%

TRDA-5761.0%

Cash

IVVD$160M

TRDA$99M

Debt

IVVD$0

TRDA$0

Net Cash/Debt

IVVD$160M

TRDA$99M

Current Ratio (TTM)

IVVD5.87x

TRDA10.89x

Quick Ratio (TTM)

IVVD5.60x

TRDA10.47x

Debt/Equity (TTM)

IVVD0.00x

TRDA0.00x

Debt/Assets (TTM)

IVVD0.0%

TRDA0.0%

Interest Coverage (TTM)

IVVDN/A

TRDAN/A

Net Debt/EBITDA (TTM)

IVVD0.00x

TRDA0.00x

Beta

IVVD1.32

TRDA-0.22

52W Performance

IVVD-56.0%

TRDA-8.0%

YTD Performance

IVVD-71.2%

TRDA-43.6%

% from 52W High

IVVD-76.5%

TRDA-65.5%

% from 52W Low

IVVD36.7%

TRDA10.1%

Asset Turnover (TTM)

IVVD0.27x

TRDA0.01x

FCF Yield (TTM)

IVVD-51.6%

TRDA-61.4%

Earnings Yield (TTM)

IVVD-50.5%

TRDA-75.3%

Dividend Yield (TTM)

IVVDN/A

TRDAN/A

Rule of 40

IVVD-161.6

TRDA-2,977.3

EV/GP/RG

IVVD0.06

TRDAN/A

Ticker research

View IVVD research View TRDA research

Metric	IVVD Invivyd Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$212M	$220M
Enterprise Value	$52M	$121M
Price	$0.72	$5.67
P/E Ratio	N/A	N/A
P/S Ratio	3.64x	46.97x
EV/Sales	0.90x	25.79x
EV/EBITDA	0.00x	15.47x
P/B Ratio	1.34x	0.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.48x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.13x	5.15x
Revenue & Growth
Revenue (TTM)	$58M	$5M
Revenue Growth (YoY)	26.3%	-94.1%
Forward Rev Growth	44.8%	124.9%
Profitability
Gross Margin (TTM)	92.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-191.7%	-3686.8%
Net Margin (TTM)	-183.9%	-3537.7%
FCF Margin (TTM)	-187.9%	-2883.2%
Net Income (TTM)	$-107M	$-166M
FCF (TTM)	$-110M	$-135M
EPS (TTM)	-$0.33	-$3.93
ROE (TTM)	-5973.0%	-5761.0%
ROA (TTM)	-4897.0%	-4654.0%
ROIC (TTM)	-5973.0%	-5761.0%
Financial Health
Cash	$160M	$99M
Debt	$0	$0
Net Cash/Debt	$160M	$99M
Current Ratio (TTM)	5.87x	10.89x
Quick Ratio (TTM)	5.60x	10.47x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.32	-0.22
52W Performance	-56.0%	-8.0%
YTD Performance	-71.2%	-43.6%
% from 52W High	-76.5%	-65.5%
% from 52W Low	36.7%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.27x	0.01x
FCF Yield (TTM)	-51.6%	-61.4%
Earnings Yield (TTM)	-50.5%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-161.6	-2,977.3
EV/GP/RG	0.06	N/A
Ticker research	View IVVD research	View TRDA research